A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Turin, Italy
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
University of Southern California
Incyte Corporation
University Hospital, Brest